Unicycive Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $675,000 | $951,000 | — |
| Selling, general & administrative | — | — | — | $383,000 | $245,000 |
| Research and development | $9.1M | $20.0M | $12.9M | $12.4M | $6.1M |
| Operating expenses | $29.5M | $32.1M | $21.4M | $19.0M | $9.0M |
| Operating income | -$29.5M | -$32.1M | -$20.8M | -$18.1M | -$9.0M |
| Interest expense | $71,000 | $71,000 | $82,000 | $6,000 | $628,000 |
| Net income | -$26.6M | -$36.7M | -$30.5M | -$18.1M | -$10.0M |
| Balance Sheet | |||||
| Cash and equivalents | $29.2M | $26.1M | — | $455,000 | $16.6M |
| Current assets | $49.0M | $30.9M | $13.4M | $2.6M | $18.4M |
| Total assets | $49.1M | $31.7M | $14.2M | $2.8M | $18.7M |
| Current liabilities | $18.9M | $24.1M | $17.5M | $3.3M | $2.1M |
| Total liabilities | $18.9M | $24.2M | $18.0M | $3.3M | $2.3M |
| Stockholders' equity | $30.2M | $7.4M | -$3.8M | -$466,000 | $16.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$31.3M | -$28.6M | -$18.3M | -$15.7M | -$5.8M |
| Depreciation and amortization | $34,000 | $22,000 | $9,000 | $428,000 | $468,000 |
| Stock-based compensation | $2.6M | $2.4M | $1.8M | $1.0M | $966,000 |
| Capital expenditure | $24,000 | $72,000 | $12,000 | $2,000 | $29,000 |
| Free cash flow | -$31.3M | -$28.6M | -$18.3M | -$15.7M | -$5.8M |
| Dividends paid | — | $1.1M | $900,000 | — | — |
Shares outstanding 26.7M · Free float 74.1%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.